2024
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
Taylor M, Reddy S, Ashok Kumar P, Hariri D, Sokol E, Sivakumar S, Quintanilha J, Pavlick D, Levy M, Ross J, Lustberg M. Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2024, 42: 1092-1092. DOI: 10.1200/jco.2024.42.16_suppl.1092.Peer-Reviewed Original ResearchTriple negative breast cancerComprehensive genomic profilingGenomic alterationsHER2 statusHER2 2Triple negative breast cancer groupGA frequencyReview of pathology specimensHER2 IHC expressionHER2-low statusHER2-low tumorsLack of clinical dataPD-L1 expressionTumor mutational burdenHER2 IHC scoreHER2 2+Negative breast cancerEvaluate genomic alterationsMann-Whitney U testPotential treatment optionStatistically significant differenceHER2 subgroupsPD-L1Immunotherapy biomarkersChi-square test
2023
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)
Ruddy K, Zahrieh D, He J, Waechter B, Holleran J, Lewis L, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo H, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars In Oncology 2023, 50: 7-10. PMID: 36693773, PMCID: PMC10247389, DOI: 10.1053/j.seminoncol.2023.01.001.Peer-Reviewed Original ResearchConceptsMTOR inhibitor-associated stomatitisDexamethasone mouthwashCoprimary endpointsTrough concentrationsExact testRandomized phase III trialEverolimus trough concentrationsPrior clinical researchPhase III trialsDose-limiting toxicityFisher's exact testMann-Whitney U testWilcoxon rank sum testRank sum testOral everolimusIII trialsOral stomatitisTreatment periodMouth rinseMTOR inhibitorsPoor enrollmentClinical researchEverolimusU testStomatitis